PH30794A - Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof. - Google Patents

Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof.

Info

Publication number
PH30794A
PH30794A PH48651A PH48651A PH30794A PH 30794 A PH30794 A PH 30794A PH 48651 A PH48651 A PH 48651A PH 48651 A PH48651 A PH 48651A PH 30794 A PH30794 A PH 30794A
Authority
PH
Philippines
Prior art keywords
worthmannin
phosphatidylinositol
analogs
kinase
inhibition
Prior art date
Application number
PH48651A
Other languages
English (en)
Inventor
Bonjouklian Rosanne
Powis Garth
Vlahos Chris John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH30794A publication Critical patent/PH30794A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PH48651A 1993-07-19 1994-07-15 Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof. PH30794A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (1)

Publication Number Publication Date
PH30794A true PH30794A (en) 1997-10-17

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
PH48651A PH30794A (en) 1993-07-19 1994-07-15 Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof.

Country Status (16)

Country Link
US (1) US5378725A (cs)
EP (1) EP0635268A1 (cs)
JP (1) JPH0753370A (cs)
KR (1) KR950002755A (cs)
CN (1) CN1111127A (cs)
AU (1) AU678831B2 (cs)
CA (1) CA2128046A1 (cs)
CZ (1) CZ283806B6 (cs)
HU (1) HUT67667A (cs)
IL (1) IL110325A0 (cs)
NO (1) NO942641L (cs)
PH (1) PH30794A (cs)
PL (1) PL304317A1 (cs)
RU (1) RU94026082A (cs)
TW (1) TW287102B (cs)
ZA (1) ZA945103B (cs)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
EP1072273B1 (en) * 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
JP2003523166A (ja) * 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
CA2359244C (en) * 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1289472A4 (en) * 2000-05-30 2004-09-08 Advanced Res & Tech Inst COMPOSITIONS AND METHODS FOR IDENTIFYING MODULATORS OF PTEN FUNCTION AND PI-3 KINASE MECHANISMS
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US20040213757A1 (en) * 2003-04-23 2004-10-28 Wyeth Holdings Corporation Water soluble wortmannin derivatives
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US20090305236A1 (en) * 2005-05-11 2009-12-10 Genetic Technologies Limited Methods of enriching fetal cells
JP2008545670A (ja) * 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20080199441A1 (en) * 2006-11-09 2008-08-21 Tony Peled Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2548253T3 (es) * 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
NO942641L (no) 1995-01-20
CZ169294A3 (en) 1995-02-15
CA2128046A1 (en) 1995-01-20
TW287102B (cs) 1996-10-01
PL304317A1 (en) 1995-01-23
IL110325A0 (en) 1994-10-21
HUT67667A (en) 1995-04-28
CN1111127A (zh) 1995-11-08
CZ283806B6 (cs) 1998-06-17
EP0635268A1 (en) 1995-01-25
NO942641D0 (no) 1994-07-14
RU94026082A (ru) 1996-05-20
HU9402128D0 (en) 1994-09-28
KR950002755A (ko) 1995-02-16
US5378725A (en) 1995-01-03
ZA945103B (en) 1996-03-27
JPH0753370A (ja) 1995-02-28
AU678831B2 (en) 1997-06-12
AU6754094A (en) 1995-01-27

Similar Documents

Publication Publication Date Title
PH30794A (en) Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof.
EP0648492A3 (en) Inhibition of phosphatidylinositol-3-kinase with viridin, dimethoxyviridin, viridiol, dimethoxyviridiol, virone, wortmannolone, and their derivatives.
AU2855092A (en) Corrosion and/or scale inhibition
EP0525610A3 (en) Process for increasing the stability of enzymes and stabilized enzymes
AU1371992A (en) Substituted diphenylethylenes and analogues or derivatives thereof
GB9323054D0 (en) Determination of the surface properties of an omject
GB9314822D0 (en) Determination of position
HK19496A (en) Use of 1,2,2,3,3-penta-fluoropropane
AU3728889A (en) Corrosion inhibition
HU9600241D0 (en) Mutable composition and methods of use thereof
YU102589A (en) Compound and use thereof
AU6723294A (en) Use of simmondsine
AU6809594A (en) Colletotrichum and use thereof
GB9222985D0 (en) Use of the tarchonanthus camphoratus
AU3070192A (en) Uses of 1,1,1,3,3,3-hexafluoropropane
EP0644716A4 (en) Medical uses of trioxolane and diperoxide compounds.
GB2219078B (en) Identifying the position of objects or zones
AU3612489A (en) Corrosion inhibition
GB8905800D0 (en) Prevention of condensation
ZA904825B (en) Inhibition of potato-sprouting
AU622666B2 (en) Identifying the position of objects or zones
GB9308077D0 (en) Assay of 2,4-dinitrophenylhydrazones and related compounds
GB2256270B (en) Determination of the condition of or change in state of an environment
ZA893367B (en) Identifying the position of objects or zones
ZA944932B (en) Use of phenalkylamines